POMALYST® (pomalidomide) is similar to thalidomide and is used together with dexamethasone (PVd) in the treatment of patients with multiple myeloma who have previously received at least two therapies, including lenalidomide and proteasome inhibitors and have shown positive signs within 60 days after the completion of the last treatment or in the longer future.
Multiple myeloma is a blood cancer that repeatedly relieves and relapses. It is a rare and invasive disease with patients accounting for 1% of all cancer patients. About 114,000 people worldwide have been diagnosed with multiple myeloma every year and about 80,000 people die each year due to the disease. Multiple myeloma is the second most common blood cancer in the United States and is usually considered a disease that can be controlled by treatment but is incurable. Over time, this disease slowly develops resistance to existing treatments and becomes refractory. Therefore, patients are in urgent need of new treatments.
OPTIMISMM evaluated the efficacy and safety of POMALYST/IMNOVID (pomalidomide) plus bortezomib and low-dose dexamethasone with bortezomib and low-dose dexamethasone in the treatment of patients with relapsed/refractory multiple myeloma. This is the only 3-phase clinical trial of a triple therapy study in all patients who have received lenalidomide (REVLIMID®) therapy, and there are significant medical needs in some patients.
We hope the research and development of the combination therapy will proceed smoothly and bring new therapeutic gospel to patients with multiple myeloma as soon as possible.
Reference: WuXi PharmaTech's Courier | Significant Improvement in PFS and Positive Outcomes after the 3-Phase Multiple Myeloma Therapy
February 9th, 2018